Preetha Madhukumar
Overview
Explore the profile of Preetha Madhukumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim H, Leong L, Tan Y, Ong E, Tan V, Lim S, et al.
Singapore Med J
. 2023 Dec;
PMID: 38037778
No abstract available.
2.
Ong S, Ho P, Khng A, Lim E, Wong F, Tan B, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681694
Background: The hypothesis that breast cancer (BC) susceptibility variants are linked to chemotherapy-induced toxicity has been previously explored. Here, we investigated the association between a validated 313-marker-based BC polygenic risk...
3.
Lim J, Sim Y, Ngeow J, Yuen J, Tan V, Tan B, et al.
ANZ J Surg
. 2022 Apr;
92(6):1440-1446.
PMID: 35470542
Introduction: Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to...
4.
Sim Y, Lim C, Phyu N, Tan K, Chew L, Wong C, et al.
Front Oncol
. 2022 Apr;
12:835320.
PMID: 35433431
Introduction: Statins, HMG-CoA reductase inhibitors, are commonly used cholesterol-lowering medications which are also increasingly recognized to have anti-cancer properties for various cancers, including breast cancer. Most clinical evidence supports a...
5.
Bong T, Tan J, Ho J, Tan P, Lau W, Tan T, et al.
J Breast Cancer
. 2022 Feb;
25(1):37-48.
PMID: 35199500
Purpose: This study identified factors predicting malignant upgrade for atypical ductal hyperplasia (ADH) diagnosed on core-needle biopsy (CNB) and developed a nomogram to facilitate evidence-based decision making. Methods: This retrospective...
6.
Linn Y, Tay T, Tan E, Wong J, Madhukumar P
Breast Dis
. 2022 Jan;
41(1):151-154.
PMID: 35068435
Primary breast carcinomas often present as ill-defined, infiltrative lesions which may contain calcifications, whereas metastatic cancers from non-mammary sites are often more well-circumscribed, sharply demarcated from the adjacent breast tissue...
7.
Loo S, Toh L, Xie W, Pathak E, Tan W, Ma S, et al.
Sci Adv
. 2021 Oct;
7(41):eabh2443.
PMID: 34613780
Cell state transitions control the functional behavior of cancer cells. Epithelial-to-mesenchymal transition (EMT) confers cancer stem cell-like properties, enhanced tumorigenicity and drug resistance to tumor cells, while mesenchymal-epithelial transition (MET)...
8.
Lim S, Kusumawidjaja G, Mohd Ishak H, Tan B, Tan S, Hamzah J, et al.
Breast Cancer Res Treat
. 2021 Aug;
189(3):837-843.
PMID: 34342766
Purpose: Studies that report equivalent oncologic outcomes of sentinel lymph node biopsy (SLNB) alone versus axillary lymph node dissection (ALND) for T1-2N1mi breast cancers are heavily weighted with patients who...
9.
Wong F, Wong R, Zhou S, Ong W, Pek P, Yap Y, et al.
Lancet Reg Health West Pac
. 2021 Jul;
6:100065.
PMID: 34327401
Background: Socioeconomic status (SES) is likely to affect survival in breast cancer patients. Housing value is a reasonable surrogate for SES in Singapore where most residents own their own homes,...
10.
Zou R, Loke S, Tan V, Quek S, Jagmohan P, Tang Y, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33925125
Mammography is extensively used for breast cancer screening but has high false-positive rates. Here, prospectively collected blood samples were used to identify circulating microRNA (miRNA) biomarkers to discriminate between malignant...